TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00390910

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine GSK1024850A
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine GSK1024850A
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine GSK1024850A
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Description: Intramuscular injection, 3 doses
Study: NCT04596696

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Rotavac
Description: Rotavac Is a monovalent vaccine containing suspension of live attenuated rotavirus 116E strain, a naturally occurring reassortant strain G9P\[11\], containing one bovine rotavirus gene P\[11\] and 10 human rotavirus genes prepared in Vero cells administered orally at 6, 10 and 14 weeks of age.
Study: NCT01620112

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: high Clonidine concentration
Description: Clonidine 1 ml - 150 mcg on 20 ml de lidocaine 1,5% on axillary brachial plexus block for upper limb surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low clonidine concentration
Description: Clonidine 1 ml - 150 mcg on 40 ml of lidocaine 1,5% - single injection on axillary brachial plexus block for upper limb

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine 1,5% 20 ml 300 mg for single injection on axillary brachial plexus block for upper lim surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 40 ml
Description: Lidocaine 40 ml 1,5% 600 mg single injection for axillary brachial plexus block for upper limb surgery
Study: NCT02440230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OFS + Anastrozole
Description: Ovarian function suppression can be achieved by choice of goserelin at a dose of 3.6 mg administered by means of subcutaneous injection every 28 days,bilateral oophorectomy,or bilateral ovarian irradiation.~Patients will take anastrozole 1mg qd.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OFS + Exemestane
Description: Patients will take exemestane 25mg qd. Ovarian function suppression can be achieved by choice of goserelin at a dose of 3.6 mg administered by means of subcutaneous injection every 28 days,bilateral oophorectomy,or bilateral ovarian irradiation.
Study: NCT03163485

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dialytrode
Description: Multimodal neuromonitoring by intracerebral depth EEG recording combined with microdialysis for the sampling of cerebrospinal fluid during EEG recording

Intervention type: DEVICE
Group type: OTHER
Intervention: Standard treatment
Description: Monitoring of intracranial pressure by EVD and/or multimodal neuromonitoring by microdialysis for sampling of cerebrospinal fluid
Study: NCT05134051

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave® Intravascular Lithotripsy System (Shockwave Medical Inc)
Description: IVL is a novel balloon catheter-based device that utilises pulsatile mechanical energy to disrupt calcified lesions. IVL differs from other types of lithotripsy with respect to depth of penetration. It is a single-use, sterile, disposable balloon catheter. The emitters convert electrical energy into transient acoustic circumferential pressure pulses that disrupt both superficial and deep calcium within plaque. The balloon catheter is connected to the generator, which is programmed to deliver the specified dosage of pulses. The IVL balloon, sized 1:1 to the reference artery ratio, is inflated low pressure (4 atm) with 10 pulses of ultrasound energy of 10s delivered per balloon. The procedure is repeated to provide a minimum of 20 pulses in the target lesion, with interval deflation to allow distal perfusion. Each catheter can emit a max of 80 pulses at a rate of one pulse per second. If the lesion exceeds the 12mm balloon length, the balloon can be repositioned and the IVL repeated.
Study: NCT02960841

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intracavitary Manual Lymphatic Drainage

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Study: NCT02849288

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bigfoot Biomedical Type 1 Diabetes Management System (T1DMS)
Description: Automated Insulin Delivery System
Study: NCT04740554

Intervention type: BEHAVIORAL
Intervention: Duchenne Muscular Dystrophy group with Deflazacort
Description: Subjects with duchenne muscular dystrophy undergoing drug therapy with Deflazacort

Intervention type: BEHAVIORAL
Intervention: Duchenne Muscular Dystrophy group with Prednisone/Predisolone
Description: Subjects with duchenne muscular dystrophy undergoing drug therapy with Prednisona/Predinisolone

Intervention type: BEHAVIORAL
Intervention: Duchenne Muscular Dystrophy group without Corticosteroids therapy
Description: Control group with duchenne muscular dystrophy without the use of corticosteroid drug therapy.

Intervention type: BEHAVIORAL
Intervention: Control Group Typically Developing
Description: Control group with tipical development.
Study: NCT00675805

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Infusomat filter (Codan Duofilter-Set V86-P)
Description: An approved filter system may be efficient in retaining complement activating IgG aggregates in IVIG preparations. This effect may reduce complement activation and consecutive inflammation thereby diminishing adverse events during application of intravenous immunoglobulins.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: IVIG application without filter (Placebo)
Description: Application Intravenous immunoglobulins without filter (Placebo)
Study: NCT01377753

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visualase Thermal Therapy System
Description: Used for performing Laser Induced Thermal Therapy to destroy malignant or unwanted tissue by delivering laser energy sufficient to cause coagulation and necrosis of the tissue.
Study: NCT01668511

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABT-981
Description: Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABT-981
Description: Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABT-981
Description: Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABT-981
Description: Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Injection
Study: NCT01829399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine with Epinephrine
Description: 10-15 mL 0.25% Bupivicaine with epinephrine 1:200,000 subcutaneous axillary ring

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal Saline
Study: NCT01377051

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indacaterol maleate
Description: Dry powered, 300 mcg, only one inhalation with 24 hours duration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dry powered, same to study drug, only one inhalation
Study: NCT00879112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB07811
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB07811
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB07811
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study: NCT02132546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Study: NCT00330265

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KC-002
Description: Determine the safety and effectiveness of a device (the KC-002 interactive wound dressing) in the promotion of healing in diabetic foot ulcers as compared with a conventional wound therapy regimen for subjects with Type 1 or Type 2 diabetes mellitus.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Wound Therapy
Description: Normal Saline Dressings
Study: NCT00763737

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fetoscopic Endoluminal Tracheal Occlusion
Description: prenatal balloon placement at 30-31+6 weeks and removal at 34-34+6 wks
Study: NCT00346268

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine, Parecoxib
Description: Parecoxib 40 milligrams (mg) administered intravenously immediately post surgery, followed 20 mg every 12 hours until 48 hours post surgery, total 5 doses. Participants also received Patient-Controlled Analgesia (PCA) 1 mg per dose, maximum 40 mg/4 hours, and if necessary, bolus (2 to 5 mg) before or after enabled PCA.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine, Placebo
Description: Matching placebo administered intravenously immediately post surgery and every 12 hours until 48 hours post surgery, total 5 doses. Participants also received PCA (1 mg per dose, maximum 40 mg/4 hours, and if necessary, bolus (2 to 5 mg) before or after enabled PCA
Study: NCT02839200

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem
Description: Over-encapsulated zolpidem tablet at a strength of 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 1
Description: Placebo capsules matching ACT-541468 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 1
Description: Placebo capsules matching ACT-541468 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 1
Description: Placebo capsules matching ACT-541468 capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1
Description: Placebo capsules matching ACT-541468 capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 2
Description: Placebo capsules matching over-encapsulated zolpidem
Study: NCT02008799

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow stem cell injection
Description: Injection should be in testis and testicular artery
Study: NCT01198496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan, Losartan and HCTZ, Amlodipine , Spironolactone
Description: \<Study drugs and treatment steps\> Step 1: Losartan 50 mg in principle (other ARB is usable) Step 2: Combination drug containing losartan 50 mg and hydrochlorothiazide 12.5 mg Step 3: Combination drug containing losartan 50mg and HCTZ 12.5mg + amlodipine 5 mg Step 4: Losartan 50 mg + combination drug containing losartan 50 mg and HCTZ 12.5 mg + amlodipine 5 mg Step 5: Losartan 50 mg + combination drug containing losartan 50 mg and HCTZ 12.5 mg + amlodipine 10 mg Step 6: Losartan 50 mg + combination drug containing losartan 50 mg and HCTZ 12.5 mg + amlodipine 10 mg + spironolactone 25 mg
Study: NCT04466319

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rocking Chair
Description: Patients in the experimental group were sat rocking chair three times a day in a rocking wooden chair in addition to their postoperative routine care by their nurses. After providing the rocking chair to the patients' room, the researcher gave the data collection form to be filled by the patient himself. It was the researcher's supervision that the patient sat in the rocking chair for the first time. The rocking chair movement continued to intervene until the patient released gas. After emitting gas, he continued to swing in the rocking chair until he made his first stools. The patient was visited every day until he was discharged. No special clothing or materials were required for the patients to sit in the rocking chair.
Study: NCT02643212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03873142

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Parenting
Description: The mindful parenting intervention is an adaption for parents of the Mindfulness-Based Cognitive Therapy (MBCT) for depression (Kabat-Zinn, 1990), and the Mindful-Based Stress Reduction program (MBSR; Kabat-Zinn, 1990). The mindful parenting intervention will follow the manual developed by Bögels and Restifo (2014). The intervention consists of 9x3hour sessions. Eight of these sessions are run on consecutive weeks and the final session is run eight weeks after the eighth session. These groups involve group discussions around parenting, meditation exercises, and yoga, amongst other things.
Study: NCT02417402

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The patients allocated to the Control group will be treated by physical therapists who did not carry out the training before treatment. The physical therapists will use their usual care for nonspecific chronic low back pain. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week). Each treatment session has an estimated duration of 50-60 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trained
Description: The patients allocated to the Experimental group will be treated by physical therapists who carried out the training before treatment. The training will be designed to guide the physical therapists beliefs and attitudes to a biopsychosocial model; update knowledge contained in clinical practice guidelines; and enable physical therapists to identify, integrate and address psychosocial factors in patients with nonspecific chronic low back pain. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week). Each treatment session has an estimated duration of 50-60 minutes.
Study: NCT00235547

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: timing of initiation of transdermal patch after an abortion
Description: the initiation of the patch after abortion is dictated by the study as opposed to offering several options (i.e. first Sunday of period). For this arm it is to place the patch in the clinic with clinic staff before leaving the clinic

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: timing of initiation of transdermal patch after an abortion
Description: the initiation of the patch after abortion is dictated by the study as opposed to offering several options (i.e. first Sunday of period). For this arm it is to place the patch in the clinic with clinic staff before leaving the clinic
Study: NCT01924728

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic stimulation
Description: 50Hz active magnetic stimulation (coil position 100%) delivered to the pelvic floor muscles

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham magnetic stimulation
Description: 50Hz sham magnetic stimulation (coil position 0%) delivered to the pelvic floor muscles
Study: NCT03897244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose dual therapy (rabeprazole, amoxicillin)
Description: High-dose dual therapy (rabeprazole 20 mg qid + amoxicillin 750 mg qid, for 14 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth High-dose dual therapy (rabeprazole, amoxicillin, tripotassium dicitrate bismuthate)
Description: Bismuth-High-dose dual therapy (rabeprazole 20 mg qid + amoxicillin 750 mg qid + tripotassium dicitrate bismuthate 300 mg qid, for 14 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin-Metronidazole Bismuth quadruple therapy
Description: Amoxicillin-Metronidazole Bismuth quadruple therapy (rabeprazole 20 mg bid + tripotassium dicitrate bismuthate 600 mg bid + amoxicillin 1000 mg bid + metronidazole 500 mg tid, for 14 days)
Study: NCT02359877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-054

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rebif

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avonex
Study: NCT01919814

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Appethyl™
Description: Four hours after breakfast participants will be given a small amount of liquid to drink that will contain Appethyl™. They will not know which they are getting and it will be decided randomly, like flipping a coin. Participants will be presented with a pizza in a quantity more than they could reasonably be expected to eat 5 hours after the start of their lunch meal and be asked to eat to their satisfaction over 30 minutes. Participants are not expected to eat all of the pizza.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Appethyl™
Description: Four hours after breakfast participants will be given a small amount of liquid to drink that will contain Appethyl™. They will not know which they are getting and it will be decided randomly, like flipping a coin. Participants will be presented with a pizza in a quantity more than they could reasonably be expected to eat 5 hours after the start of their lunch meal and be asked to eat to their satisfaction over 30 minutes. Participants are not expected to eat all of the pizza.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Four hours after breakfast, participants will be given a small amount of liquid to drink that will contain a placebo (inactive liquid). Participants will not know which they are getting and it will be decided randomly, like flipping a coin. Participants will be presented with a pizza in a quantity more than they could reasonably be expected to eat 5 hours after the start of their lunch meal and be asked to eat to their satisfaction over 30 minutes. They are not expected to eat all of the pizza.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Four hours after breakfast, participants will be given a small amount of liquid to drink that will contain a placebo (inactive liquid). Participants will not know which they are getting and it will be decided randomly, like flipping a coin. Participants will be presented with a pizza in a quantity more than they could reasonably be expected to eat 5 hours after the start of their lunch meal and be asked to eat to their satisfaction over 30 minutes. They are not expected to eat all of the pizza.
Study: NCT03890718

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photorefractive keratectomy in mile keratoconus
Description: Topo-guided photorefractive keratectomy will be performed using an excimer laser (Allegretto Wave Topolyzer, Alcon, Inc.) with a 6 mm optical area and a transition area of 2 mm in all eyes. At that point, the partial topography-guided photorefractive keratectomy laser treatment will be finished. The arrangement will be to treat 70% of the cylindrical and spherical part to not surpass 50μm of stromal expulsion. The estimation of 50μm as the most extreme removal depth recommended by Kanellopoulos in Athens protocol will be chosen
Study: NCT00275262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate depot (LAD) 11.25 mg 3 Month
Description: LAD intramuscular injection 11.25 mg, 3 month duration. To stimulate immune response, a subcutaneous key limpet hemocyanin (KLH) vaccination injection (1 mg) was administered at Month 6.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched placebo
Description: Matched placebo intramuscular injection, 3 month duration. To stimulate immune response, a subcutaneous key limpet hemocyanin (KLH) vaccination injection (1 mg) was administered at Month 6.
Study: NCT00597298

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Threshold
Description: Inspiratory muscle training program using a variable pressure device. An inspiratory muscle training device comprises a chamber having an opening for the passage of air to be inhaled and exhaled, and an inlet permitting air to be inhaled to enter the chamber and to pass to the opening. A one-way exhaust valve permits exhaled air entering through the opening to escape from the chamber, and another valve is provided to resist the entry of air to be inhaled into the chamber, the latter valve serving to vary the degree of resistance in dependence upon the volume of air that has passed through the inlet.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham threshold
Description: non-training physical activity
Study: NCT02839642

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivastigmine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01422226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Experimental: 400 mcg taken sublingually 2 hours prior to IUD insertion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pill identical to study drug in appearance, taste, smell. Taken sublingually 2 hours prior to IUD insertion
Study: NCT00133887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rapamycin
Description: 3 to 5 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ciclosporine
Description: Blood residual level \< or = to 125 ng/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: Blood residual level \< or = to 8 ng/ml
Study: NCT01817153

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrocortison hemisuccinate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo followed by hydrocortisone hemisuccinate
Study: NCT03545958

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity Interval Training (HIT)
Description: Following the mind-motor training component, participants in the experimental group will then continue in the 45-minute HIT intervention, which will be composed by a 10-minute warm-up, a 25-minute core activity, and a 10-minute cool down. The 25-minute core activity will be carried out based on a 4 x 4 minutes aerobic interval training model. The intensity in each cycle will be prescribed at an individual level, and training heart rates will be determined via a sub-maximal excise testing at baseline and monitored during exercise using a wrist-based heart rate monitor (Suunto). In order to ensure progression in aerobic training over the 6-month intervention, training heart rates will be recalculated at the intervention midpoint (i.e., 3 months), where a new sub-maximal exercise test will be performed. Participants will exercise 60 minutes/day, 3 days/week for 6 months.
Study: NCT02707731

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hydrokinesiotherapy
Description: physical therapy technique used in a plastic bucket approved by ANVISA , with water temperature monitored at 37 ° C, water level up to the shoulders and by the physical properties of water, was allowed to mobilize the newborn facilitating the feeling of relaxation and standard suitable movement.